# Verdiva Bio funding rounds and investors

As of 14 Oct 2026, Verdiva Bio has raised $411M across 1 verified round on record; latest: $411 million Series A led by Forbion and General Atlantic, announced 9 Jan 2025.

Verdiva Bio develops next-generation medicines aimed at treating obesity and cardiometabolic diseases.

Website: https://verdivabio.com  
Headquarters: London and San Francisco  
Page: https://fireround.dev/companies/verdivabio.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2025-01-09 | Series A | $411 million | Forbion, General Atlantic | Lilly Asia Ventures, Logos Fund, Lyfe Capital, OrbiMed, RA Capital Management | [bioindustry.org](https://www.bioindustry.org/resource/verdiva-bio-launches-with-over-410m-in-series-a-financing-to-advance-next-generation-therapies.html) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.